Oyster Mushroom Extract Shows Potent Anticancer Activity Against Breast Cancer Cells

A humble edible mushroom from the Pleurotus family has delivered a striking result in the laboratory. In a new peer-reviewed study published in BMC Complementary Medicine and Therapies, researchers report that a methanolic extract of Pleurotus eous, a species of oyster mushroom prized in culinary traditions across Asia and beyond, killed human breast cancer cells in a dose-dependent manner while also displaying powerful antioxidant behavior. The work, led by Mohammed Al Qutaibi of Ibb University in Yemen together with Suresh R. Kagne of Dr. Babasaheb Ambedkar Marathwada University in India, adds an intriguing new candidate to the growing roster of fungi being screened for molecules that might one day complement conventional cancer therapy. The findings are early and preliminary, confined entirely to cells in a dish, but the numbers behind them are arresting enough to warrant a closer look at what this mushroom contains and how the team measured its effects.

The research team began with a straightforward question: if edible mushrooms are increasingly recognized as reservoirs of bioactive anticancer compounds, what might P. eous hold? The species is known to be rich in phenolic and terpenoid constituents, two broad chemical families with well-documented biological activity, yet its potential against cancer cells had never been systematically evaluated. To answer the question, the investigators prepared a methanolic extract of the mushroom fruiting bodies and subjected it to gas chromatography-mass spectrometry, or GC-MS, a technique that vaporizes chemical compounds and separates them by mass, allowing researchers to identify individual molecules within a complex mixture. The spectral data, matched against reference libraries maintained by the National Institute of Standards and Technology, revealed a phytochemical profile that immediately caught the authors’ attention.

Among the compounds identified were carvacrol, quinic acid, and a derivative of cinnamic acid. Each of these molecules carries an established scientific pedigree. Carvacrol, the monoterpene phenol that gives oregano and thyme their characteristic aroma, has been repeatedly studied for antimicrobial, antioxidant, and pro-apoptotic effects in cancer models. Quinic acid, a cyclitol found in coffee and many plants, is a building block of chlorogenic acid and has been linked to anti-inflammatory and chemopreventive activity. Cinnamic acid derivatives, meanwhile, appear throughout the plant and fungal kingdoms and have been investigated for their ability to interfere with tumor cell proliferation. The presence of all three in a single mushroom extract suggested that P. eous might be more than an ordinary culinary fungus, prompting the team to move from chemical identification to biological testing.

The first biological assay targeted oxidative chemistry. The researchers used the DPPH assay, a widely employed colorimetric test in which the purple-colored free radical 2,2-diphenyl-1-picrylhydrazyl loses its absorbance when neutralized by antioxidants. The results were dramatic: at a concentration of 700 micrograms per milliliter, the P. eous extract scavenged 97.39 percent of the DPPH radicals, an efficiency approaching that of synthetic reference antioxidants. Complementing this, the team measured total phenolic content using the Folin-Ciocalteu assay, which quantifies phenolic compounds by their ability to reduce a phosphotungstic-phosphomolybdic acid reagent, expressed here in gallic acid equivalents. The extract yielded a total phenolic content of 2.80 plus or minus 0.04 milligrams of gallic acid equivalent per gram of dry weight. The strong radical-scavenging performance is consistent with the idea that phenolic compounds donate hydrogen atoms or electrons to stabilize reactive radicals, a mechanism thought to contribute to chemoprevention by protecting cellular DNA from oxidative damage.

The centerpiece of the study, however, was the cytotoxicity testing against MCF-7 cells, one of the most extensively characterized human breast cancer cell lines in existence. Originally isolated in 1970 from a patient with invasive breast carcinoma, MCF-7 cells are estrogen-receptor positive and serve as a standard in vitro model for hormone-responsive breast cancer, the most common malignancy in women worldwide. The researchers cultured the cells in Dulbecco’s Modified Eagle Medium supplemented with fetal bovine serum and exposed them to escalating concentrations of the mushroom extract. Cell viability was quantified with the MTT assay, a metabolic test in which living cells reduce a yellow tetrazolium salt into purple formazan crystals; the amount of formazan produced serves as a proxy for the number of metabolically active, surviving cells. Doxorubicin, a mainstay anthracycline chemotherapy drug, served as the positive control against which the extract’s performance could be benchmarked.

The outcome was unambiguous. The extract killed MCF-7 cells in a dose-dependent fashion, achieving a half-maximal inhibitory concentration, or IC50, of 82.69 micrograms per milliliter at the 24-hour time point. In pharmacological terms, the IC50 represents the concentration of a compound required to reduce cell viability by half, and values in the low tens to hundreds of micrograms per milliliter are considered meaningful starting points for natural product screening. Microscopic examination of the treated cultures revealed morphological changes characteristic of apoptosis, the programmed cell death pathway that cancer cells often evade. Cells exposed to higher concentrations of the extract displayed the shrinkage, rounding, and detachment that pathologists associate with cells undergoing self-destruction rather than simple toxic necrosis. Statistical analysis by analysis of variance followed by Tukey’s post-hoc test confirmed that the differences between treated and untreated groups were highly significant, with a p-value below 0.0001, meaning the probability that the observed effect arose by chance is vanishingly small.

The authors attribute the extract’s dual antioxidant and cytotoxic activity to its phenolic and terpenoid content, and the mechanistic logic is plausible. Phenolic compounds can act as pro-oxidants at high intracellular concentrations, tipping the redox balance of cancer cells, which already live under elevated oxidative stress, past the point of no return and triggering apoptotic signaling. Terpenoids such as carvacrol have been shown in other systems to disrupt mitochondrial membrane potential, activate caspase enzymes, and interfere with cell cycle progression. Quinic acid derivatives may contribute through modulation of inflammatory pathways that sustain tumor growth. It is important to stress, however, that the present study identifies associations rather than definitive mechanisms. The extract is a mixture of many compounds, and the specific molecule or combination of molecules responsible for killing MCF-7 cells has not yet been isolated or proven.

That caveat leads directly to the study’s stated limitations and next steps. The authors are explicit that further in vivo studies and compound purification are needed to confirm the observed effects and to clarify the underlying mechanisms. In vitro cell culture, while indispensable for screening, cannot capture the pharmacokinetics of a real organism: how a compound is absorbed, distributed, metabolized, and excreted, whether it reaches tumor tissue at active concentrations, and whether it harms healthy cells along the way. A crude methanolic extract that kills cancer cells in a dish may contain molecules that are too toxic, too unstable, or too poorly absorbed to ever become medicine. The purification pipeline, typically involving high-performance liquid chromatography fractionation followed by bioassay-guided testing, will be essential to isolate the active principles and determine whether a single compound or a synergistic ensemble is responsible.

Nevertheless, the study lands at a moment of surging interest in fungi as pharmaceutical factories. Mushrooms occupy a unique ecological niche as decomposers, and their evolutionary pressure to produce defensive secondary metabolites has equipped them with an extraordinary chemical arsenal. Established drugs derived from fungi include the statins, the immunosuppressant cyclosporine, and antibiotics such as penicillin, while mushroom-derived polysaccharides like lentinan from shiitake have been approved as adjuvant cancer therapies in some countries. Edible oyster mushrooms of the Pleurotus genus are particularly attractive candidates because they are cheap to cultivate on agricultural waste, fast-growing, and already consumed safely by millions of people, which simplifies the safety profile questions that plague many natural product candidates.

For now, the message for the public is one of measured enthusiasm rather than self-medication. Eating oyster mushrooms will not deliver the concentrated, chemically characterized extract tested in this study, and no clinical evidence yet supports any therapeutic use of P. eous in cancer patients. What the research does provide is a rigorous, statistically robust foundation for the next phase of investigation: isolating the active molecules, testing them against normal cells to establish selectivity, validating the findings in animal models, and ultimately, if the results hold, advancing toward clinical evaluation. Breast cancer remains one of the most prevalent malignancies worldwide, and the search for new agents, particularly those derived from accessible natural sources, remains urgent. A mushroom that most people walk past in the grocery aisle may, with enough scientific scrutiny, turn out to harbor chemistry worth far more than its weight in the produce bin. The journey from laboratory dish to pharmacy shelf is long and uncertain, but every credible candidate discovered along the way improves the odds.

Subject of Research: Anticancer and antioxidant potential of Pleurotus eous mushroom extract against human breast cancer MCF-7 cells in vitro

Article Title: Evaluation of the anticancer potential of Pleurotus eous against human breast cancer MCF-7 cell line

Article References: Al Qutaibi, M., & Kagne, S. R. (2026). Evaluation of the anticancer potential of Pleurotus eous against human breast cancer MCF-7 cell line. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05582-1

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05582-1

Keywords: Pleurotus eous, oyster mushroom, breast cancer, MCF-7, anticancer, antioxidant, GC-MS, MTT assay, carvacrol, phenolic compounds, apoptosis, natural products